Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Effect of Albumin Platelet-Rich Fibrin or Leucocyte- Platelet-Rich Fibrin on Immediate Implant

NCT06863051 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-08-20
Last updated
2025-08-01

Condition(s) studied

Immediate Implant Placement

Investigational drug(s) / intervention(s)

Immediate Implant Placement and Alb-PRFImmediate Implant Placement and L-PRF

Immediate Implant Placement and Alb-PRF: Immediate Implant Placement in lower molar region, Grafted with Xenograft and Albumin PRF Gel

Immediate Implant Placement and L-PRF: Immediate Implant Placement in lower molar region, Grafted with Xenograft and L-PRF

Study summary

The objective of this study will be to compare between Immediate Implant grafted with xenograft and Alb-PRF gel versus xenograft with L-PRF.

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
1. Inclusion criteria * The presence of non-restorable mandibular molar. * Patient 18-45 years old * Intact buccal and lingual walls * Good oral hygiene. * Prescence of sufficient restorative space. * Jumping gap more than 2 mm. 2. Exclusion criteria * Proximity of anatomical structures * Acute localized infection (suppuration at the surgical field) * Patients on chemotherapy or radiotherapy. * Patients who have systemic disorders (diseases) {diabetes mellitus, autoimmune disease, …etc}, * Pregnant patients. * Smoking and Alcohols. * Presence of periapical pathology affecting the neighboring teeth.

Primary outcome measure(s)

  • Vertical peri-implant bone level — Immediate Post-Operative and 6 months after surgery
    the distance between implant platform to the most coronal bone-implant contact
  • Keratinized tissue Width — Immediate Post-Operative and 6 months after surgery
    Width of Keratinized tissue before and after surgery
  • Crestal bone level — Immediate Post-Operative and 6 months after surgery
    distance between implant platform and bone crest

Trial sites (1)

FacilityCityRegionStatus
Kafrelsheikh University, Faculty of Dentistry Kafr ash Shaykh Kafrelsheikh Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06863051 on ClinicalTrials.gov ↗ ← All trials in Egypt